Meeting Overview - The company will hold a shareholder meeting on September 17, 2025, at 14:30 in Kunming, Yunnan Province [1] - The meeting will utilize a combination of on-site and online voting methods [1] - The online voting system will be available from 9:15 to 15:00 on the day of the meeting [1][2] Voting Procedures - Shareholders can vote through the Shanghai Stock Exchange's online voting system, either via trading terminal or internet platform [2] - Shareholders with multiple accounts can aggregate their voting rights across all accounts [3] - Duplicate votes through different methods will be counted based on the first vote cast [3] Attendance Requirements - Only shareholders registered by the close of business on September 10, 2025, are eligible to attend the meeting [4] - Shareholders must complete registration in advance to ensure smooth proceedings [4] Proxy Voting - Shareholders can appoint a proxy to attend and vote on their behalf, with specific documentation required for both natural and legal persons [4][5] - The proxy must indicate their voting intention on the proxy form [7]

Core Viewpoint - The company, Jianzhijia Pharmaceutical Chain Group Co., Ltd., will hold a half-year performance briefing on August 29, 2025, to discuss its operational and financial status for the first half of 2025, addressing common investor concerns [2][3][4]. Group 1: Meeting Details - The performance briefing is scheduled for August 29, 2025, from 10:00 AM to 11:00 AM [4][6]. - The meeting will take place at the Shanghai Stock Exchange Roadshow Center and will be conducted in an interactive online format [6][5]. - Participants will include the company's Chairman and General Manager, Mr. Lan Bo, the Secretary of the Board and Chief Financial Officer, Mr. Li Heng, and Independent Director, Mr. Guan Yunhong [4]. Group 2: Investor Participation - Investors can participate in the briefing online via the Shanghai Stock Exchange Roadshow Center on the scheduled date [5][6]. - Investors are encouraged to submit questions from August 22 to August 28, 2025, through the Roadshow Center's website or via the company's email [5][6]. - The company will address commonly asked questions during the briefing [3][5]. Group 3: Contact Information - For inquiries, investors can contact Mr. Li Heng at phone number 0871-65711920 or via email at ir@jzj.cn [7]. - After the briefing, the main content and details will be available on the Shanghai Stock Exchange Roadshow Center [7].

Group 1 - The company will hold a half-year performance briefing on August 29, 2025, from 10:00 to 11:00 AM [1][2] - The briefing will take place at the Shanghai Stock Exchange Roadshow Center and will be conducted in an interactive online format [2][3] - Key personnel attending the briefing include the Chairman and General Manager, Mr. Lan Bo, the Secretary of the Board and CFO, Mr. Li Heng, and the Independent Director, Mr. Guan Yunhong [2] Group 2 - Investors can submit questions for the briefing from August 22, 2025, to August 28, 2025, by visiting the Roadshow Center website or emailing the company [3] - During the briefing, the company will address common concerns from investors regarding its operational performance and financial status for the first half of 2025 [2][3] - After the briefing, investors can access the main content and details of the event through the Roadshow Center [3]

Core Viewpoint - The company is disposing of assets through its wholly-owned subsidiary, Qinhuangdao Tangren Pharmaceutical Chain Co., Ltd., by selling land use rights and building ownership for a total price of RMB 24 million [2][10][12]. Group 1: Transaction Overview - The transaction involves the sale of industrial land use rights and building ownership located in Qinhuangdao, with a total estimated transfer price of RMB 24 million [2][10]. - The transaction does not constitute a related party transaction or a major asset restructuring, and it was approved by the board of directors without the need for shareholder approval [3][8][18]. - The decision to close the Qinhuangdao logistics center and consolidate operations at the Hebei Tangshan logistics center is aimed at improving logistics efficiency and cost control [4][7][16]. Group 2: Asset Details - The asset being transferred includes a land use area of approximately 22,999.98 square meters and a building with a total area of 10,691.23 square meters [10][11]. - The assessed value of the building is approximately RMB 14.34 million, while the land use rights are valued at approximately RMB 9.66 million, totaling around RMB 23.99 million [11][12]. Group 3: Financial Impact - The disposal of the asset is expected to enhance asset utilization efficiency and improve the company's financial situation by recovering funds [16][17]. - The transaction is not anticipated to negatively impact the company's financial or operational status, nor will it harm the interests of shareholders [17][18]. Group 4: Transaction Process - The transaction will occur in three phases, with the first phase requiring a 30% deposit of the total price, followed by subsequent payments and the transfer of ownership [12][13][14]. - The final payment is due by November 30, 2025, and the asset transfer is scheduled for August 31, 2025 [13][14].

Core Viewpoint - The company Jianzhijia (605266) announced the sale of industrial land use rights and associated buildings for a total price of 24 million yuan, which aligns with its business development strategy and aims to improve asset efficiency and control distribution costs [1] Group 1 - The subsidiary Qinhuangdao Tangren Pharmaceutical Chain Co., Ltd. is selling the land use rights and buildings located in the northern industrial area of Qinhuangdao City [1] - The expected transfer price for the assets is 24 million yuan [1] - The disposal of these assets is intended to enhance the company's financial situation by recovering funds [1]

Core Insights - The article emphasizes the transition of store operations from traditional models to a data-driven, intelligent decision-making approach, highlighting the importance of network stability as a foundational support for digital operations [1][22]. Group 1: Static IP as the "Network Foundation" for Digital Operations - Static IP addresses provide physical isolation for each store, avoiding risks associated with dynamic IPs, such as frequent disconnections and data synchronization failures [3][4]. - Static IP ensures 24/7 uninterrupted operations, supporting critical services like payment systems and security systems without downtime [5][6]. - The traceability of static IPs enhances security management by allowing for IP-based access control and detailed logging of network activities [7][8]. Group 2: Management Upgrades Driven by Static IP - Inventory management evolves from manual counting to intelligent alerts, with real-time data synchronization between ERP systems and headquarters [10][11]. - Security management shifts from reactive measures to proactive prevention, utilizing AI for real-time monitoring and alerting [12][13]. - Customer operations transition from broad marketing strategies to targeted engagement through data analysis, enhancing customer experience and loyalty [14]. Group 3: Long-term Value of Static IP - Direct benefits include cost reduction and efficiency gains, with significant savings reported in operational costs and reduced business interruption losses [20][21]. - Indirect benefits enhance brand competitiveness, improving customer satisfaction and compliance with regulatory requirements [21][22]. - Static IP is positioned as a necessary component for digital transformation in retail and other sectors, with a return on investment typically realized within 8-12 months for brands with annual revenues exceeding 50 million [22].

Summary of Key Points Core Viewpoint - The company has signed multiple guarantee contracts to support its wholly-owned subsidiaries in obtaining financing, with a total guarantee amount not exceeding 8 billion RMB, aimed at enhancing operational efficiency and independent business capabilities [1][3][6]. Group 1: Guarantee Agreements - The company has entered into a maximum guarantee contract with Hengfeng Bank for its subsidiary Yunnan Jianzhijia Chain Health Pharmacy, with a maximum debt guarantee amount of 50 million RMB [1]. - A guarantee contract was signed with the Export-Import Bank for the same subsidiary, with a maximum debt guarantee amount of 40 million RMB [2]. - The company has also signed a guarantee contract with Industrial Bank for its subsidiary Guangxi Qinkang, with a maximum debt guarantee amount of 60 million RMB [2]. - A guarantee agreement was made with China Merchants Bank for its subsidiary Sichuan Qinkang, with a maximum guarantee amount of 20 million RMB [2]. Group 2: Internal Decision-Making Process - The company held board meetings and a shareholder meeting to approve the proposal for comprehensive credit limits and guarantees, allowing for a total credit limit of up to 8 billion RMB [3][4]. - The approved credit limit includes 5.5 billion RMB for daily operations and 2.5 billion RMB for specific projects [3]. Group 3: Necessity and Reasonableness of Guarantees - The guarantees are deemed necessary to support the subsidiaries' operational development and financing needs, which will enhance overall financing efficiency and independent operational capabilities [6]. - The company maintains sufficient control over its subsidiaries, allowing for effective monitoring and management of associated risks [6]. Group 4: Board Opinions - The board believes that the guarantees align with the company's development plans and are essential for the subsidiaries' operational funding needs, ensuring smooth business operations [7]. - The guarantees do not involve external parties and are considered manageable in terms of risk [7]. Group 5: Cumulative Guarantee Amounts - As of the announcement date, the total amount of guarantees provided to wholly-owned subsidiaries is 1.913574 billion RMB, representing 68.41% of the company's audited net assets for the year 2024 [8]. - The company has no overdue external guarantees as of the announcement date [9].

证券日报网讯 8月12日晚间，健之佳发布公告称，近日，公司为全资子公司云南健之佳连锁健康药房有 限公司、广西健之佳勤康医药销售有限公司、四川勤康健之佳医药有限责任公司提供连带责任担保，最 高担保金额分别为9000万元、6000万元、2000万元。截至本公告披露日，本公司对全资子公司提供的担 保总额为191，357.4万元，占公司2024年度经审计净资产的比例为68.41%。 （编辑 李家琪） ...

中国经济网北京8月7日讯漱玉平民（301017）(301017.SZ)昨日晚间发布公告称，公司于近日收到公司 控股股东、实际控制人、董事长李文杰出具的《关于股份减持计划的意向函》。 漱玉平民上市发行费用为5981.83万元，其中保荐及承销费用4439.96万元。 2025年4月29日，公司披露的《关于2024年度募集资金存放与使用情况的专项报告》显示，经中国证券 监督管理委员会《关于同意漱玉平民大药房连锁股份有限公司向不特定对象发行可转换公司债券注册的 批复》(证监许可〔2022〕2869号)核准，公司向不特定对象发行面值总额8.00亿元可转换公司债券，期 限6年，每张面值100元，共计800.00万张，募集资金总额为人民币800,000,000.00元，扣除发行费用人民 币9,415,851.41元(不含增值税)后，实际募集资金净额为人民币790,584,148.59元。 漱玉平民上市以来两次募集资金合计11.59亿元。 2024年年度报告显示，漱玉平民报告期内营业总收入为95.70亿元，同比增长4.13%；归属于上市公司股 东的净利润为-1.89亿元，去年同期为1.33亿元；归属于上市公司股东的扣除非经常 ...

Group 1 - A new pet supplies company, Xuzhou Aizhi Jia Pet Supplies Co., Ltd., has been established with a registered capital of 1 million yuan [1] - The business scope of the new company includes internet information services, road cargo transportation (network freight), food sales, food internet sales, and veterinary drug management [1] - The company is wholly owned by Xuzhou Enhua Unified Pharmaceutical Chain Sales Co., Ltd., which is a subsidiary of Enhua Pharmaceutical (002262) [1]